If drugmakers have their way, the federal government likely ends up spending $100 billion of taxpayer funds to bail out rural hospitals.

This approach would aim to raise the same amount of revenue that was previously generated by covered entities’ arbitrage of 340B drugs without the perverse incentives perpetuated by the current ...

The American Society of Health-System Pharmacists is urging lawmakers to protect the 340B Drug Pricing Program, warning that changes to the discount model could destabilize safety-net hospitals. In an ...

Even as they sparred on broader healthcare policy and funding topics fueling the ongoing government shutdown, senators of the ...

Discount drug program requires drug companies to sell deeply discounted drugs to hospitals that serve high numbers of ...

AHA writes to express our strong support for this vital program that allows eligible hospitals to maintain, improve and expand access to essential services and medications for the patients and ...

The Senate Committee on Health, Education, Labor and Pensions Oct. 23 held a hearing ( discussing the 340B program and its growth and impacts on patients.

Inaccurate information, pushbacks and undue limitations imposed by pharmaceutical manufacturers pose a threat to the 340B ...

HRSA is piloting a 340B rebate model similar to one that it just fought against. As the agency dips its toes into the 340B debate, hospital groups express concerns about the potential for cash flow ...

For the 5,000 people in Illinois living with sickle cell disease, access to affordable medical care and life-saving ...